| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2189 | 2017 |
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study PA Ascierto, D Schadendorf, C Berking, SS Agarwala, CML van Herpen, ... The lancet oncology 14 (3), 249-256, 2013 | 752 | 2013 |
| Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study SJ O'Day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, ... Annals of Oncology 21 (8), 1712-1717, 2010 | 622 | 2010 |
| Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings F Belli, A Testori, L Rivoltini, M Maio, G Andreola, MR Sertoli, G Gallino, ... Journal of Clinical Oncology 20 (20), 4169-4180, 2002 | 540 | 2002 |
| Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial R Dummer, D Schadendorf, PA Ascierto, A Arance, C Dutriaux, ... The Lancet Oncology 18 (4), 435-445, 2017 | 460 | 2017 |
| Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled … PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ... The Lancet Oncology 21 (11), 1465-1477, 2020 | 435 | 2020 |
| Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab PF Ferrucci, PA Ascierto, J Pigozzo, M Del Vecchio, M Maio, ... Annals of Oncology 27 (4), 732-738, 2016 | 400 | 2016 |
| Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity G Pietra, C Manzini, S Rivara, M Vitale, C Cantoni, A Petretto, M Balsamo, ... Cancer research 72 (6), 1407-1415, 2012 | 369 | 2012 |
| Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma J Shi, XR Yang, B Ballew, M Rotunno, D Calista, MC Fargnoli, P Ghiorzo, ... Nature genetics 46 (5), 482-486, 2014 | 347 | 2014 |
| Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity M Balsamo, F Scordamaglia, G Pietra, C Manzini, C Cantoni, M Boitano, ... Proceedings of the National Academy of Sciences 106 (49), 20847-20852, 2009 | 341 | 2009 |
| Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ... The Lancet Oncology 15 (4), 436-444, 2014 | 316 | 2014 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022 | 299 | 2022 |
| Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial AM Di Giacomo, PA Ascierto, L Pilla, M Santinami, PF Ferrucci, ... The lancet oncology 13 (9), 879-886, 2012 | 295 | 2012 |
| Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio, V Atkinson, H Schmidt, ... Nature medicine 25 (6), 941-946, 2019 | 294 | 2019 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The lancet oncology 22 (5), 643-654, 2021 | 289 | 2021 |
| Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma E Simeone, G Gentilcore, D Giannarelli, AM Grimaldi, C Caracò, ... Cancer immunology, immunotherapy 63, 675-683, 2014 | 274 | 2014 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 226 | 2018 |
| Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide S Walpole, AL Pritchard, CM Cebulla, R Pilarski, M Stautberg, ... JNCI: Journal of the National Cancer Institute 110 (12), 1328-1341, 2018 | 208 | 2018 |
| Natural killer cells kill human melanoma cells with characteristics of cancer stem cells G Pietra, C Manzini, M Vitale, M Balsamo, E Ognio, M Boitano, P Queirolo, ... International immunology 21 (7), 793-801, 2009 | 198 | 2009 |
| Uveal melanoma F Spagnolo, G Caltabiano, P Queirolo Cancer treatment reviews 38 (5), 549-553, 2012 | 194 | 2012 |
Diana GiannarelliFondazione Policlinico Universitario A. Gemelli IRCCS Romepoliclinicogemelli.it의 이메일 확인됨
